Biocartis Group Valuation
Is 0R72 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0R72 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 0R72's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 0R72's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0R72?
Key metric: As 0R72 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0R72's PS Ratio? | |
|---|---|
| PS Ratio | 0.4x |
| Sales | €60.82m |
| Market Cap | €27.24m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.5x |
| Enterprise Value/EBITDA | -4.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0R72's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.4x | ||
OBI Ondine Biomedical | 24.2x | 66.0% | UK£22.9m |
POLX Polarean Imaging | 12.6x | 49.6% | UK£18.7m |
IHC Inspiration Healthcare Group | 0.4x | 13.6% | UK£14.1m |
AGL ANGLE | 16.3x | 51.5% | UK£33.1m |
0R72 Biocartis Group | 0.4x | 22.3% | €27.2m |
Price-To-Sales vs Peers: 0R72 is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (20.8x).
Price to Sales Ratio vs Industry
How does 0R72's PS Ratio compare vs other companies in the GB Medical Equipment Industry?
Price-To-Sales vs Industry: 0R72 is good value based on its Price-To-Sales Ratio (0.4x) compared to the UK Medical Equipment industry average (3.3x).
Price to Sales Ratio vs Fair Ratio
What is 0R72's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.4x |
| Fair PS Ratio | 0.3x |
Price-To-Sales vs Fair Ratio: 0R72 is expensive based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Arjo
SEK 9.3b
Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.
0HQ8
SEK 34.02
7D
0.4%
1Y
-6.6%
Centene
US$30.5b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
0HVB
US$61.32
7D
4.8%
1Y
-17.1%
Elevance Health
US$93.4b
Operates as a health benefits company in the United States.
0HG8
US$409.11
7D
2.1%
1Y
-14.2%